Cargando…
Gabapentin Enacarbil Extended‐Release Versus Placebo: A Likely Responder Reanalysis of a Randomized Clinical Trial
BACKGROUND: We reanalyzed a multisite 26‐week randomized double‐blind placebo‐controlled clinical trial of 600 mg twice‐a‐day Gabapentin Enacarbil Extended‐Release (GE‐XR), a gabapentin prodrug, designed to evaluate safety and efficacy for treating alcohol use disorder. In the original analysis (n =...
Autores principales: | Laska, Eugene M., Siegel, Carole E., Lin, Ziqiang, Bogenschutz, Michael, Marmar, Charles R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540534/ https://www.ncbi.nlm.nih.gov/pubmed/33460198 http://dx.doi.org/10.1111/acer.14414 |
Ejemplares similares
-
Gabapentin enacarbil extended release for the treatment of postherpetic neuralgia in adults
por: Thomas, Ben M, et al.
Publicado: (2013) -
Gabapentin Enacarbil: Pharmacotherapy of Restless Legs Syndrome
por: Jones, Ruth, et al.
Publicado: (2010) -
Gabapentin enacarbil – clinical efficacy in restless legs syndrome
por: Agarwal, Pinky, et al.
Publicado: (2010) -
Role of gabapentin enacarbil XR in restless legs syndrome
por: Sivam, Sheila, et al.
Publicado: (2012) -
Review of the Treatment of Restless Legs Syndrome: Focus on Gabapentin Enacarbil
por: Burke, Rachel A., et al.
Publicado: (2012)